Josh Jennings
Stock Analyst at Morgan Stanley
(2.67)
# 1,898
Out of 4,820 analysts
14
Total ratings
54.55%
Success rate
18.14%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Josh Jennings
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| DCBO Docebo | Maintains: Overweight | $49 → $53 | $31.91 | +66.09% | 5 | Nov 10, 2023 | |
| PODD Insulet | Maintains: Outperform | $350 → $300 | $260.59 | +15.12% | 3 | Aug 9, 2023 | |
| BFLY Butterfly Network | Initiates: Outperform | $20 | $2.43 | +724.74% | 1 | Jun 21, 2021 | |
| MDWD MediWound | Initiates: Outperform | $63 | $17.99 | +250.19% | 1 | Sep 28, 2017 | |
| CTSO Cytosorbents | Initiates: Outperform | $7 | $1.09 | +542.20% | 1 | Jun 7, 2017 | |
| EW Edwards Lifesciences | Maintains: Outperform | $43 → $40 | $76.04 | -47.40% | 3 | Dec 7, 2016 |
Docebo
Nov 10, 2023
Maintains: Overweight
Price Target: $49 → $53
Current: $31.91
Upside: +66.09%
Insulet
Aug 9, 2023
Maintains: Outperform
Price Target: $350 → $300
Current: $260.59
Upside: +15.12%
Butterfly Network
Jun 21, 2021
Initiates: Outperform
Price Target: $20
Current: $2.43
Upside: +724.74%
MediWound
Sep 28, 2017
Initiates: Outperform
Price Target: $63
Current: $17.99
Upside: +250.19%
Cytosorbents
Jun 7, 2017
Initiates: Outperform
Price Target: $7
Current: $1.09
Upside: +542.20%
Edwards Lifesciences
Dec 7, 2016
Maintains: Outperform
Price Target: $43 → $40
Current: $76.04
Upside: -47.40%